Clinical trial
Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus…
NCT01079364 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT01079364 |
|---|---|
| Title | Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting |
| Official title | Better Acceptance of a Single Injection Apidra (Insulin Glulisine) Added to Once Daily Lantus (Insulin Glargine) Versus Twice Daily Premixed Insulin in a Real Life Use Setting |
| Acronym | BASAAL PLUS |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Insulin glulisine, Insulin glargine, Premixed insulin (Insulin Aspart 30/70 ) |
| Enrollment | 52 |
| Start date | Jan 1, 2010 |
| Primary completion | Jul 1, 2012 |
| Completion | Jul 1, 2012 |
| First posted | Mar 3, 2010 |
| Last update posted | May 29, 2013 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: